CLSI releases three new editions of antifungal papers

Antifungal Document Protectors

The Clinical and Laboratory Standards Institute (CLSI) has announced the release of three new editions of antifungal documents.

The new supplements include lists of yeast and mold species with known intrinsic (natural) resistance to antifungals for which testing is not required.

—Philippe J. Dufresne, PhD, RMCCM

MALVERN, PENNSYLVANIA, USA, August 25, 2022 /EINPresswire.com/ — The Clinical and Laboratory Standards Institute (CLSI) has announced the release of three new editions of antifungal documents: M57S—Epidemiological cut-off values ​​for antifungal susceptibility testing, 4th edition, M27M44S— Performance standards for antifungal susceptibility testing of yeast, 3rd edition, and M38M51S—Performance standards for antifungal susceptibility testing of filamentous fungi, 3rd edition.

M57S includes epidemiological cut-off values ​​(ECV) and quality control tables developed according to the guidelines of CLSI document M57. These ECVs are valid only when developed according to CLSI M57 and when minimum inhibitory concentrations or minimum effective concentrations are generated according to the reference broth dilution methods described in CLSI M27 and M38.

M27M44S—Performance standards for yeast antifungal susceptibility testing include minimum inhibitory concentration, zone diameter, and quality control tables developed according to the guidelines in CLSI documents M27 and M44. The data in the tables is only valid if the methodologies of CLSI documents M27 and M44 are followed.

M38M51S—Performance standards for antifungal susceptibility testing of filamentous fungi include minimum inhibitory concentration and quality control tables developed in accordance with the guidelines in CLSI documents M38 and M51. The data in the tables is only valid if the methodologies of CLSI documents M38 and M51 are followed.

Users should replace previously published tables with new tables in M57S, M27M44S, and M38M51S. Changes to tables since the publication of previous editions appear in bold.

“This is the result of two years of work by CLSI volunteer experts,” said Philippe J. Dufresne, PhD, RMCCM, vice-chair of the CLSI subcommittee on antifungal susceptibility testing and member of the panels. work on antifungal thresholds and antifungal epidemiological threshold values. . “The new supplements include lists of yeast and mold species with known intrinsic (natural) resistance to antifungals for which testing is not required. They also include long-awaited recommendations on body sites for Candida spp. According to site of infection and antifungals for tailoring and better treatment advice for clinicians Finally, 37 new epidemiological threshold values ​​(ECV) have been published in M57S for clinically important yeasts without breakpoints antifungals, including those for emerging and multidrug-resistant Candida auris.

CLSI sets the standard for quality in medical laboratory testing. A not-for-profit organization, CLSI unites the global laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine.
For more than 50 years, our members, volunteers and customers have made CLSI a respected and transformative leader in the development and implementation of medical laboratory testing standards. Through our unified efforts, we will continue to set and maintain the standards that promote quality test results, improve the delivery of patient care, and improve healthcare around the world.
By using CLSI standards, laboratory workers can improve process quality, accelerate the development of standard operating procedures, and implement safer practices with greater ease and efficiency.

Joanne Christopher
CLSI
+1 484-588-5907
[email protected]
Visit us on social media:
Facebook
Twitter
LinkedIn